Cetrorelix

Gonadotropin-releasing hormone (GnRH) antagonists such as cetrorelix are actually used to prevent premature ovulation during in vitro fertilization (IVF) treatment.

GnRH antagonists work by blocking the GnRH receptors in the pituitary gland, which prevents the release of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). These hormones are responsible for stimulating the growth and development of follicles in the ovaries, which contain eggs.

By preventing premature ovulation, GnRH antagonists help to ensure that the follicles are able to mature and develop properly, which increases the chances of a successful IVF cycle. They are typically administered in the later stages of ovarian stimulation, when the follicles are nearing maturity.

Compared to GnRH agonists, which can cause an initial increase in gonadotropin secretion before down-regulating it, GnRH antagonists act quickly and do not cause this initial surge in hormone levels. This makes them a useful option for patients who are at high risk of ovarian hyperstimulation syndrome (OHSS), a potentially serious complication of IVF treatment.

At Aashakiran IVF, GnRH antagonists such as cetrorelix are used as a part of their IVF treatment protocol to prevent premature ovulation and improve the chances of a successful pregnancy. Their experienced fertility specialists carefully monitor the patient's hormone levels and adjust the medication dosage as needed to ensure the best possible outcome.

In summary, GnRH antagonists such as cetrorelix are used to prevent premature ovulation during IVF treatment by blocking the GnRH receptors in the pituitary gland. At Aashakiran IVF, their experienced fertility specialists use these medications as a part of their comprehensive IVF treatment protocol to optimize the chances of a successful pregnancy.